Collagen crosslinking for keratoconus may receive FDA approval in 2012

OD's need to follow this. There is no reason we cannot be leaders in this area of care. Walt 

Source: news-medical.net 

Patients in the United States who have the cornea-damaging disease keratoconus may soon be able to benefit from a new treatment that is already proving effective in Europe and other parts of the world. The treatment, called collagen crosslinking, improved vision in almost 70 percent of patients treated for keratoconus in a recent three-year clinical trial in Milan, Italy. The treatment is in clinical trials in the United States and is likely to receive FDA approval in 2012. The results of the Milan study are being presented today at the 115th Annual Meeting of the American Academy of Ophthalmology in Orlando, Florida. 

http://bit.ly/rpD3Uk